Tirzepatide Shortage Ended: What the FDA Rules Mean Now

2026 FDA & compounding update

Tirzepatide Shortage Ended: What the FDA Rules Mean Now

The October 2024 shortage story has changed substantially. FDA ultimately reaffirmed that the tirzepatide injection shortage was resolved, and the temporary enforcement-discretion periods tied to that shortage have ended.

Medically reviewed by Dr. Timothy Mackey
Medical Director · Updated September 2026

What happened after the October 2024 announcement?

FDA first announced on October 2, 2024 that the tirzepatide shortage was resolved. That decision was challenged in court and temporarily reevaluated. On December 19, 2024, FDA issued a new determination again concluding that the shortage was resolved.

FDA then allowed temporary enforcement discretion to reduce treatment disruption. For tirzepatide, the applicable shortage-based grace periods ultimately ended in 2025.

What does “shortage resolved” mean for compounding?

When an FDA-approved drug is on the shortage list, federal law can provide broader flexibility for certain compounding activity. Once the shortage ends, that shortage-based flexibility narrows significantly.

For state-licensed pharmacies and physicians operating under section 503A, compounded drugs generally cannot be made regularly or in inordinate amounts if they are essentially copies of commercially available FDA-approved products. Individual-patient prescriptions and genuine clinical differences still matter.

For 503B outsourcing facilities, use of bulk drug substances is more restricted. Tirzepatide is not currently on the FDA drug-shortage list, and FDA has stated it does not currently appear on the 503B bulks list.

Can a 503A pharmacy still compound tirzepatide for an individual patient?

Potentially, depending on the facts. Section 503A is not a blanket ban on all individualized compounding. A prescription may qualify when it is genuinely tailored for an individual patient and is not simply an essentially identical copy of a commercially available product made routinely.

The key distinction is between patient-specific compounding for a documented clinical need and routine mass production of products that are effectively copies of Zepbound or Mounjaro.

What about adding B12 or changing concentration?

A minor formulation change does not automatically make a compounded drug legally distinct. FDA looks at whether the compounded product is essentially a copy and whether a change produces a clinically significant difference for the individual patient as determined by the prescriber.

Simply adding another ingredient or changing concentration for marketing purposes should not be assumed to satisfy federal compounding requirements.

What is the current FDA position on 503B tirzepatide?

FDA stated in 2026 that tirzepatide does not currently appear on the 503B bulks list or the drug-shortage list. FDA also proposed excluding tirzepatide, semaglutide and liraglutide from the 503B bulks list after concluding it had not identified a clinical need for outsourcing facilities to compound them from bulk substances.

The proposed exclusion is not itself a final determination. The existing shortage and bulk-substance requirements still apply.

Are compounded tirzepatide products FDA-approved?

No. Compounded medications are not FDA-approved products. They do not undergo the same premarket review for safety, effectiveness, quality, labeling and manufacturing consistency as Zepbound or Mounjaro.

That does not mean compounding has no legitimate role in medicine. It means patients should understand exactly what they are receiving, why a compounded product is being prescribed and which pharmacy is dispensing it.

Does this mean patients must use Zepbound or Mounjaro?

Not necessarily in every case, but FDA-approved products are generally the default when they are commercially available and clinically appropriate. A compounded alternative requires a legally supportable reason under applicable federal and state law.

For obesity treatment, Zepbound is the FDA-approved tirzepatide brand. Mounjaro contains tirzepatide but is approved for type 2 diabetes.

What happened to the old pricing assumptions?

Manufacturer savings programs, direct-pay options, clinic models and insurance coverage can materially change actual out-of-pocket cost. Patients should compare the total current cost rather than rely on 2024 list-price estimates.

What should patients ask a clinic or pharmacy in 2026?

• Is the medication FDA-approved Zepbound or Mounjaro, or is it compounded?
• If compounded, what is the specific clinical reason for compounding?
• Which pharmacy is dispensing it?
• Is the pharmacy operating under 503A or 503B?
• Does the formulation differ from an approved product in a clinically meaningful way for this patient?
• What is the total monthly cost, including dose increases, shipping, supplies and clinic fees?
• What happens if federal or state compounding rules change?

Treatment and product choices

Availability and regulatory status are only part of a treatment decision. For treatment indications, dosing, efficacy and side effects, see our tirzepatide for weight loss page.

Frequently asked questions

Is tirzepatide still on the FDA shortage list?

No. FDA determined the tirzepatide injection shortage was resolved.

Can pharmacies still compound tirzepatide?

Some individualized compounding may still be permissible when all legal requirements are met, but pharmacies cannot rely on the old shortage-based flexibility to routinely make essentially identical copies.

Is compounded tirzepatide generic Zepbound?

No. Compounded tirzepatide is not an FDA-approved generic equivalent of Zepbound.

Is Mounjaro the same as Zepbound?

They contain the same active drug, tirzepatide, but they are different branded products with different labeled indications.

Regulatory sources

• FDA: GLP-1 supply and compounding policy updates
• FDA: Compounding when drugs are on the shortage list
• FDA: Proposed exclusion from the 503B bulks list

This article is educational and summarizes federal regulatory developments as of September 2026. Compounding law is fact-specific and may change.